HPQ
52
3
WHR
64
3
ADP
65
4
BSX
61
2
NOV
52
3
ORLY
57
3
SLB
46
2
AXP
60
-3
HCA
50
2
HES
62
4
VMC
57
-5
O
35
5
XRAY
34
11
SPG
55
9
ROST
54
9
VZ
32
-2
BRK.B
33
-3
GPC
29
7
USB
44
-2
BLK
66
2
HPQ
52
3
WHR
64
3
ADP
65
4
BSX
61
2
NOV
52
3
ORLY
57
3
SLB
46
2
AXP
60
-3
HCA
50
2
HES
62
4
VMC
57
-5
O
35
5
XRAY
34
11
SPG
55
9
ROST
54
9
VZ
32
-2
BRK.B
33
-3
GPC
29
7
USB
44
-2
BLK
66
2
Financhill
Back

Relmada Therapeutics 10K Form

Sell
34

RLMD
Relmada Therapeutics

Last Price:
3.43
Seasonality Move:
-1.84%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RLMD News And Ratings

See the #1 stock for the next 7 days that we like better than RLMD

RLMD Financial Statistics

Sales & Book Value

Annual Sales: $10K
Cash Flow: $-13.26M
Price / Cash Flow: 0
Annual Sales: $2.04
Price / Book: 1.69

Profitability

EPS (TTM): -2.87000
Net Income (TTM): $-86.76M
Gross Margin: $0
Return on Equity: 0%
Return on Assets: 0%

Relmada Therapeutics Earnings Forecast

Key Relmada Therapeutics Financial Ratios

  • The Selling, General & Administrative Expenses for RLMD have been equal to 500.00% of Gross Profit Margin.
  • The Interest Expense is -9.27% of Operating Income.
  • Per Share Earnings over the last 12 years have been positive in 5 years.

Relmada Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: RLMD
CUSIP: 75955J
Website: relmada.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RLMD Technical Analysis vs Fundamental Analysis

Sell
34
Relmada Therapeutics (RLMD) is a Sell

Is Relmada Therapeutics a Buy or a Sell?